Cargando…
Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
BACKGROUND: Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055196/ https://www.ncbi.nlm.nih.gov/pubmed/35582295 http://dx.doi.org/10.4254/wjh.v14.i3.623 |
_version_ | 1784697352406171648 |
---|---|
author | Mohamed, Ghada Abdelrahman Nashaat, Ehab Hasan Fawzy, Hadeer Mohamed ElGhandour, Ahmed Mohamed |
author_facet | Mohamed, Ghada Abdelrahman Nashaat, Ehab Hasan Fawzy, Hadeer Mohamed ElGhandour, Ahmed Mohamed |
author_sort | Mohamed, Ghada Abdelrahman |
collection | PubMed |
description | BACKGROUND: Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as well as cell proliferation, differentiation, and motility. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC). AIM: To estimate the serum FGF-19 concentrations in HCC cases and assess its diagnostic performance for the detection of HCC. METHODS: We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit. RESULTS: We detected a high statistically significant difference in serum FGF-19 levels among the three groups. The highest level was observed in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 vs 125.63 ± 31.54 vs 69.60 ± 20.90 pg/mL, respectively, P ≤ 0.001). FGF-19 was positively correlated with alpha fetoprotein (AFP; r = 0.383, P = 0.003) and international normalised ratio (r = 0.357, P = 0.005), while it was negatively correlated with albumin (r = -0.500, P ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that the best cut-off point of AFP was > 8.2 ng/mL with an area under the curve (AUC) of 0.78, sensitivity of 63.33%, specificity of 83.33%, positive predictive value (PPV) of 79.2%, negative predictive value (NPV) of 69.4%, and total accuracy of 78%. However, FGF-19 at a cut-off point > 180 pg/mL had an AUC of 0.98, sensitivity of 100%, specificity of 90.0%, PPV of 90.0%, NPV of 100%, and total accuracy of 98%. CONCLUSION: FGF-19 represents a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management. |
format | Online Article Text |
id | pubmed-9055196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-90551962022-05-16 Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma Mohamed, Ghada Abdelrahman Nashaat, Ehab Hasan Fawzy, Hadeer Mohamed ElGhandour, Ahmed Mohamed World J Hepatol Observational Study BACKGROUND: Fibroblast growth factor 19 (FGF-19) is one of the founding members of the endocrine FGF subfamily. Recently, it has been the subject of much interest owing to its role in various physiological processes affecting glucose and lipid metabolism and the regulation of bile acid secretion as well as cell proliferation, differentiation, and motility. Additionally, FGF-19 secretion in an autocrine style has reportedly contributed to cancer progression in various types of malignancies including hepatocellular carcinoma (HCC). AIM: To estimate the serum FGF-19 concentrations in HCC cases and assess its diagnostic performance for the detection of HCC. METHODS: We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and HCC patients. Serum FGF-19 concentrations were measured using the Human FGF-19 ELISA kit. RESULTS: We detected a high statistically significant difference in serum FGF-19 levels among the three groups. The highest level was observed in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 vs 125.63 ± 31.54 vs 69.60 ± 20.90 pg/mL, respectively, P ≤ 0.001). FGF-19 was positively correlated with alpha fetoprotein (AFP; r = 0.383, P = 0.003) and international normalised ratio (r = 0.357, P = 0.005), while it was negatively correlated with albumin (r = -0.500, P ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that the best cut-off point of AFP was > 8.2 ng/mL with an area under the curve (AUC) of 0.78, sensitivity of 63.33%, specificity of 83.33%, positive predictive value (PPV) of 79.2%, negative predictive value (NPV) of 69.4%, and total accuracy of 78%. However, FGF-19 at a cut-off point > 180 pg/mL had an AUC of 0.98, sensitivity of 100%, specificity of 90.0%, PPV of 90.0%, NPV of 100%, and total accuracy of 98%. CONCLUSION: FGF-19 represents a possible novel non-invasive marker for HCC. It may improve the prognosis of HCC patients due to its utility in several aspects of HCC detection and management. Baishideng Publishing Group Inc 2022-03-27 2022-03-27 /pmc/articles/PMC9055196/ /pubmed/35582295 http://dx.doi.org/10.4254/wjh.v14.i3.623 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Observational Study Mohamed, Ghada Abdelrahman Nashaat, Ehab Hasan Fawzy, Hadeer Mohamed ElGhandour, Ahmed Mohamed Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma |
title | Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma |
title_full | Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma |
title_fullStr | Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma |
title_full_unstemmed | Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma |
title_short | Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma |
title_sort | assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055196/ https://www.ncbi.nlm.nih.gov/pubmed/35582295 http://dx.doi.org/10.4254/wjh.v14.i3.623 |
work_keys_str_mv | AT mohamedghadaabdelrahman assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma AT nashaatehabhasan assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma AT fawzyhadeermohamed assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma AT elghandourahmedmohamed assessmentoffibroblastgrowthfactor19asanoninvasiveserummarkerforhepatocellularcarcinoma |